



CRN SWP Business Intelligence Unit

Name of report:	Cancer Update Q2 2017/2018
Release date:	31 st October 2017
Data source(s) used:	Portfolio ODP
Data cut-off:	30th October 2017
Brief Summary:	Summary of recruitment activity to cancer sub specialty group portfolios nationally and regionally for Q2 of 2017/2018


National Urology Group Recruitment



SWP Urology Group Recruitment




Urology Group National Perspective



Urology Group National Perspective

CRN	2016/2017			2017/2018		
	Recruitment	Rank	Adj. for Pop. Rank	Recruitment	Rank	Adj. for Pop. Rank
East Midlands	572	13	14	301	8	11
Eastern	941	7	10	287	9	10
Greater Manchester	1845	1	1	523	3	1
Kent, Surrey and Sussex	1538	2	4	605	2	2
North East and North Cumbria	1234	4	3	357	7	5
North Thames	1458	3	9	641	1	6
North West Coast	319	15	15	89	15	15
North West London	843	9	2	128	13	13
South London	1039	6	5	417	5	3
South West Peninsula	665	12	7	243	11	7
Thames Valley and South Midlands	699	11	6	280	10	4
Wessex	800	10	8	237	12	9
West Midlands	847	8	12	366	6	12
West of England	354	14	13	104	14	14
Yorkshire and Humber	1206	5	11	497	4	8

Urology Group SWP Recruitment



Key Trials

- Prostate
 - Add Aspirin (any prostate RT pt or post prostatectomy pt)
 - PIVOTAL BOOST (HDR vs IMRT boost to prostate tumour and/or hypofractionated pelvic RT)
 - STAMPEDE
- Bladder
 - RAIDER (adaptive bladder radiotherapy +/- tumour boost)
 - ATLANTIS (all sites to consider opening; STAMPEDE like maintenance study following response after first line platinum based palliative chemotherapy)
- Renal
 - RAMPART (adjuvant single or combination immunotherapy post nephrectomy in patients with intermediate or high risk RCC).

The Future



- Continue to refer to Urology portfolio maps in MDT to facilitate network referrals
- <https://sites.google.com/a/nih.ac.uk/crn-south-west-peninsula/business-intelligence-unit-1/cancer-portfolio-maps/urology-portfolio>
- Immunotherapy studies being considered within the UK for high risk non-muscle invasive bladder cancers
 - Important to have this within the network
 - Need to consider how this group of patients will be managed, as will need to be seen by oncology
- All MDT members invited to the Network bladder cancer study day 26/01/2017 Exeter '*Embracing a multidisciplinary and evidence based approach*'